IDEXX Laboratories (IDXX) Surged Following Robust Earnings
Conestoga Capital Advisors, an asset administration firm, launched its third-quarter 2025 investor letter. A replica of the letter might be downloaded right here. Fairness markets continued their momentum that started in early April, reaching new all-time highs within the third quarter. The Mid Cap Composite returned -3.2% net-of-fees within the third quarter, in comparison with a 2.8% achieve for the Russell Midcap Progress Index. The technique’s deal with high-quality, worthwhile corporations struggled to maintain tempo within the quarter amid risk-on dominance. Please test the highest 5 holdings of the fund for a greater understanding of their greatest picks for 2025.
In its third-quarter 2025 investor letter, Conestoga Capital Advisors highlighted shares resembling IDEXX Laboratories, Inc. (NASDAQ:IDXX). IDEXX Laboratories, Inc. (NASDAQ:IDXX) develops, manufactures, and distributes merchandise primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets. The one-month return of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was -1.74%, and its shares gained 38.06% of their worth during the last 52 weeks. On October 21, 2025, IDEXX Laboratories Inc. (NASDAQ:IDXX) inventory closed at $637.13 per share, with a market capitalization of $50.97 billion.
Conestoga Capital Advisors acknowledged the next relating to IDEXX Laboratories Inc. (NASDAQ:IDXX) in its third quarter 2025 investor letter:
“IDEXX Laboratories Inc. (NASDAQ:IDXX) is the business chief in offering devices (and consumables) utilized in diagnostics, detection, and data programs for veterinary, meals, and water testing purposes. Earnings for the quarter have been sturdy as natural income development accelerated, regardless of weak veterinarian visits, and the corporate noticed speedy adoption of their newest premium instrument.”
IDEXX Laboratories Inc. (NASDAQ:IDXX) will not be on our checklist of 30 Most Well-liked Shares Amongst Hedge Funds. In response to our database, 48 hedge fund portfolios held IDEXX Laboratories Inc. (NASDAQ:IDXX) on the finish of the second quarter, in comparison with 51 within the earlier quarter. IDEXX Laboratories Inc.’s (NASDAQ:IDXX) income elevated 11% as reported and 9% organically within the second quarter of 2025. Whereas we acknowledge the potential of IDEXX Laboratories Inc. (NASDAQ:IDXX) as an funding, we imagine sure AI shares supply better upside potential and carry much less draw back danger. When you’re in search of a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
